Amarin Corp Plc (AMRN)

[ralphey]

Yes this conundrum of a quagmire known as vascepa ..... would enjoy others inputs on this - possible reasons ....

1.) AMRN is asking too much

2.) THey believe STevie and its 'all in the placebo'

3.) They intend to pick up the company but are waiting to drive the price lower ( IF thats the case they should be buying now at 100% premium or $6 per share)

4.) Pfizer believes its new product to be much more effective ( but again why not start now with vascepa and transition into it - studies are going to take prob 4 - 5 years )

5.) Let AMRN pay to build the concept of residual lipid risk and then step into already built market

6.) No one is aware of the med and the potential ( AMRN's fault)

7.) No one willing to fight infringement - or waiting for infringement issue to be resolved